LYEL Lyell Immunopharma, Inc.
Healthcare$16.37-6.24%ClosedMarket Cap: $382.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
13142.36
EV/EBITDA
-1.96
DCF Value
$0.89
FCF Yield
-33.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-7422.6%
Operating Margin
-618909.7%
Net Margin
-794858.1%
ROE
-85.7%
ROA
-70.3%
ROIC
-61.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.0K | -116500.0% | $-46.2M | $-24.2M | $— | — |
| Q4 null | $6.0K | 100.0% | $-61.3M | $-140.7M | $— | — |
| FY null | $36.0K | -31952.8% | $-203.8M | $-274.4M | $— | — |
| Q3 null | $15.0K | 100.0% | $-37.3M | $-38.8M | $— | — |
| Q2 null | $8.0K | 100.0% | $-47.1M | $-42.7M | $— | — |
| Q1 null | $7.0K | 100.0% | $-57.4M | $-52.2M | $— | — |
| Q4 null | $11.0K | 100.0% | $-201.1M | $-191.9M | $— | — |
| FY null | $61.0K | 100.0% | $-358.8M | $-343.0M | $— | — |
| Q3 null | $34.0K | 100.0% | $-50.5M | $-44.6M | $— | — |
| Q2 null | $13.0K | 100.0% | $-51.5M | $-45.8M | $— | — |
| Q1 null | $3.0K | 100.0% | $-55.6M | $-60.7M | $— | — |
| Q4 2023 | $13.0K | -38800.0% | $-59.8M | $-52.9M | $-0.21 | — |